Juan Andres - Dec 3, 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Dec 3, 2021
Transactions value $
-$5,536,700
Form type
4
Date filed
12/7/2021, 03:07 PM
Previous filing
Dec 3, 2021
Next filing
Dec 10, 2021
SEC
View on sec.gov

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -7.69% $0.00 60K Dec 3, 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10K -20.56% $0.00 38.6K Dec 6, 2021 Common Stock 10K $14.22 Direct F1, F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -8.33% $0.00 55K Dec 6, 2021 Common Stock 5K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 This option is fully vested and exercisable.
F3 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer